Fed Report Calls on NIH to Blaze Personalized Medicine Trail


Personalized Medicine Watch by John Russell

October 14, 2008 | It’s a busy time on the personalized medicine front. The recently-released federal government report, Priorities for Personalized Medicine, is gradually attracting attention. The state of Wisconsin last week jumped into the race to become a center for personalized medicine. And a group of technology providers has joined Scripps Translational Science Institute (STSI) to study to what extent people make behavioral changes when they are provided with genetic screening and information about their various risk factors.

Back in 2001, the President’s Council of Advisors on Science and Technology were instructed to develop suggested policy around personalized medicine’s needs. The result, Priorities for Personalized Medicine, is not all that profound—“HHS, should join with the private sector to create a public/private sector ‘Personalized Medicine R&D Roadmap’ for coordinating discovery and translational research in personalized medicine”—but it’s a start.

NIH is urged to take in lead in directing “critical investments in the enabling tools and resources essential to moving beyond genomic discoveries to personalized medicine products and services of patient and public benefit.” Specifically, the report calls on NIH to spur efforts to develop an integrated nationwide network of standardized biospecimen repositories and to fund academic/industry projects addressing biomarker standardization, statistical methods.

Meanwhile Wisconsin governor Jim Doyle today announced the Wisconsin Genomics Initiative, a collaborative research effort among the Marshfield Clinic, Medical College of Wisconsin (MCW), University of Wisconsin School of Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). Wisconsin has long been a leader in genomic research. The Marshfield Clinic has undertaken the largest population-based genetic research project in the country which approximately 20,000 people have contributed their DNA and given researchers access to their complete electronic health records.

The other big news last week was the announcement that Microsoft, Navigenics, and Affymetrix would join forces with the Scripps Translational Science Institute (STSI) to launch a novel research study to assess the behavioral impact of personal genetic testing. The goal of the study is to discover if participating in personal genomic testing improves people’s health by encouraging them to make positive lifestyle decisions and medical monitoring.

The study will offer genetic scans by Navigenics to up to 10,000 employees, friends, and family of the nonprofit Scripps Health system in San Diego and monitor participants’ changes in behavior for two decades. Participants will report their lifestyle changes at 3- and 12-month intervals after they receive their Navigenics results. They will also take part in periodic health surveys over the next two decades. A complete database of genomic and clinical information will be maintained at the Scripps Genomic Medicine program. For more read the Bio-IT World article on the program.

Related Links
Priorities for Personalized Medicine report:
http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf.

The Wisconsin initiative:
http://www.eurekalert.org/pub_releases/2008-10/mc-gda101008.php
http://www.forbes.com/feeds/ap/2008/10/10/ap5537035.html

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Digital End-To-End for Pharma
Sponsored by SAIC

Given the rapidly changing pharmaceutical industry landscape, traditional methods alone of identifying, retrieving, and analyzing the private and publicly available information no longer suffice. How can Pharma effectively harness the immense amounts of data from an ever-growing number of internal and external sources?

The Digital End-to-End white paper discusses some of the ways that Pharma can harness the power of the data to pursue novel products that are profitable, safe, and have proven value to one or more patient populations.



Adobe® LiveCycle® ES
Deploying Adobe Technology to Automate Electronic Submissions
Sponsored by Adobe
Discover how to:
  • Help reduce the cost of bringing products to market
  • Improve document collaboration across your organization
  • Satisfy global regulatory requirements, stockholder expectations, and customer demands
  • Improve data capture, information assurance, document output, process management, and content services
  • Gain a competitive advantage, get immediate ROI


Interoperability and Architecture for the Life Sciences Industry
What it will take to gain industry consensus on interchange standards, and what organizations can do today to optimize their own information architectures
Sponsored by SAS
Information technology is finally up to the task of cost-effective clinical research. But there are still some significant barriers to gaining all the benefits of this technology, in particular, interoperability. This white paper explores the need for a consistent industry architecture that allows life sciences firms to connect their enterprises and benefit from unified data integration, process consistency and rapid communication of meaningful drug findings.


Life Science Webcasts & Podcasts

Medidata Solutions

Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms

Protocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.

This podcast will discuss:

  • Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
  • Results of a recent joint Tufts University / Medidata Solutions study.
  • New metrics benchmarking protocol design trends.
  • Systematic protocol design improvements and why they are essential to clinical trial performance excellence.

Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.

Download Now



More Podcasts

Job Openings

Manager, Scientific Computing & Programming
Lead SAIC-Frederick, Inc.’s Bioinformatics & Analysis Group in developing & maintaining informatics pipelines for generation/analysis of dense genotyping & next-generation sequencing data. Required: MS or equiv. 5 yrs related experience. Knowledge of programming/software development, high performance computing, bioinformatics, project management. Visit www.saic-frederick.com - #130019.

Related Resources & Products

Multiplex Assays in Translational Medicine: Technologies, Applications, and Future Directions
Multiplex Assays in Translational Medicine: Technologies, Applications, and Future Directions
Translational Cancer Medicine
Microarrays in Medicine
Microarrays in Medicine



For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to [email protected].